PRMT1 Promotes the Self‐renewal of Leukemia Stem Cells by Regulating Protein Synthesis
Advanced Science · 2025
DOI: 10.1002/advs.202308586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Min Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, China. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplastic Stem Cells, Protein Biosynthesis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Project of Guangzhou Basic Research Program.
Abstract (Originalsprache)
The application of tyrosine kinase inhibitors (TKIs) has revolutionized the management of chronic myeloid leukemia (CML). However, disease relapse and progression particularly due to persistent leukemia stem cells (LSCs) remain a big challenge in the clinic. Therefore, validation of the therapeutic vulnerability in LSCs is urgently needed. This study verifies the critical role of protein arginine methyltransferase 1 (PRMT1) in the maintenance of CML LSCs. It is found that PRMT1 promotes the survival and serially plating abilities of human primary CML LSCs. Genetic deletion of Prmt1 significantly delays the leukemogenesis and impairs the self‐renewal of LSCs in BCR‐ABL – driven CML mice. PRMT1 regulates LSCs and leukemia development depending on its methyltransferase activity. Pharmacological inhibition of PRMT1 activity by MS023 remarkably eliminates LSCs and prolongs the survival of CML mice. Mechanistical studies reveal that PRMT1 promotes transcriptional activation of ribosomal protein L29 (RPL29) via catalyzing asymmetric dimethylation of histone H4R3 (H4R3me2a) at its gene promoter region. PRMT1 augments the global protein synthesis via RPL29 in CML LSCs. Taken together, the findings provide new evidence that histone arginine methylation modification regulates protein synthesis in LSCs and highlight PRMT1 as a valuable druggable target for patients with CML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, China.
- Jinan University Institute of Tumor Pharmacology, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
- State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, 100101, China.
- School of Life Sciences, University of Chinese Academy of Sciences, Beijing, 100049, China.
- Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China.
ORCID-Profile: Yanli Jin
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Project of Guangzhou Basic Research Program
Zitieren
APA
Zhou, M., Huang, Y., Xu, P., Li, S., Duan, C., Lin, X., Bao, S., Zou, W., Pan, J., Liu, C., & Jin, Y. (2025). PRMT1 Promotes the Self‐renewal of Leukemia Stem Cells by Regulating Protein Synthesis. Advanced Science. https://doi.org/10.1002/advs.202308586
Vancouver
Zhou M, Huang Y, Xu P, Li S, Duan C, Lin X, et al. PRMT1 Promotes the Self‐renewal of Leukemia Stem Cells by Regulating Protein Synthesis. Advanced Science. 2025. doi:10.1002/advs.202308586
BibTeX
@article{Zhou2025,
author = {Zhou, Min and Huang, Yi and Xu, Ping and Li, Shuyi and Duan, Chen and Lin, Xiaoying and Bao, Shilai and Zou, Waiyi and Pan, Jingxuan and Liu, Chang and Jin, Yanli},
title = {PRMT1 Promotes the Self‐renewal of Leukemia Stem Cells by Regulating Protein Synthesis},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202308586}
}
EUVIMED